34 results
8-K
EX-99.1
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
to address large unmet need in autoimmune disease Novel, fully human, monoclonal antibody inhibiting FcRn-mediated recycling of IgG + IMVT-1402
8-K
EX-99.2
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
FcRn- mediated recycling of IgG + IMVT-1402 ++ + + + Convenient Administration Formulated for simple subcutaneous injection that may enable self
8-K
EX-99.2
IMVT
Immunovant Inc
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
-1402 Was Selected to Deliver Maximum IgG Reduction While Minimizing Interference with Albumin Recycling
Achieve all of the above with a simple … Unmet Need in Autoimmune Disease Novel, fully human, monoclonal antibody inhibiting FcRn- mediated recycling of IgG + IMVT-1402 ++ + + + Convenient
8-K
EX-99.1
IMVT
Immunovant Inc
8 Dec 22
Regulation FD Disclosure
7:06am
and therefore greater clinical efficacy 6For Investor Audiences Only
The neonatal Fc receptor (FcRn) promotes recycling of IgG antibodies 7 FcRn Mechanism … their removal and degradation FcRn inhibition reduces the recycling of IgG antibodies As a result, IgG is increasingly delivered to lysosomes
8-K
EX-99.2
mwokqkm a90fbp2lw5
28 Sep 22
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
10:49am
8-K
EX-99.1
no5l0icjjzdw1f1mo4ic
7 Sep 22
Regulation FD Disclosure
6:39am
8-K
EX-99.1
hxskova
30 Mar 22
Regulation FD Disclosure
7:44am
424B4
iakzn3
3 Sep 20
Prospectus supplement with pricing info
12:00am
DRS
9nnrhuktln
19 Aug 20
Draft registration statement
12:00am
424B3
ra4vyv s9
29 Jun 20
Prospectus supplement
8:39am
10-K
ztndmx f75svm
29 Jun 20
Annual report
8:30am
424B4
5a2hihj
14 Apr 20
Prospectus supplement with pricing info
5:27pm
424B3
cmpx1
10 Apr 20
Prospectus supplement
6:09am
DRS
ldwixi
1 Apr 20
Draft registration statement
12:00am